Tulips Medicaments Pvt Ltd
About Tulips Medicaments Pvt Ltd
Data last updated:
Tulips Medicaments Pvt Ltd is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 18 February 1983 and has been in existence for over 43 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH1983PTC029343.
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹2 Lakh. It is led by directors including Krinita Karan Motwani and Pallavi Kirtikumar Lakdawala.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 77/4 Lakdi Bunderdarukhana Reay Road, Mumbai, Maharashtra, India – 400010.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.2 Lakh. For the same year it recorded a net loss of ₹39,038 (net margin -32.5%) and EBITDA of ₹1.01 Lakh (EBITDA margin 83.8%).
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Tulips Medicaments Pvt Ltd's registered office is in Mumbai, Maharashtra. Its e-mail address is in the company report.
- Email
- Registered Address77/4 Lakdi Bunderdarukhana Reay Road, Mumbai, Maharashtra, India – 400010
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Tulips Medicaments Pvt Ltd, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Tulips Medicaments Pvt Ltd
FY 2025 filings availableTulips Medicaments Pvt Ltd reported revenue of ₹1.2 Lakh for FY 2025.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1.01 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹39,038 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 83.8% | ||||
| Net Profit Margin | -32.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Tulips Medicaments Pvt Ltd, buy the company report.
Board of directors of Tulips Medicaments Pvt Ltd
Tulips Medicaments has 3 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Krinita Karan Motwani Also directs: Ecokrin Hygiene Private Limited, Market Resonance Private Limited | Director | 27 Mar 2010 | 16 Years 7 Months | Current |
| Pallavi Kirtikumar Lakdawala | Director | 27 Mar 2010 | 16 Years 7 Months | Current |
| Kirtikumar Manilal Lakdawala Also directs: Snoval Pharmaceuticals Pvt Ltd, Ecokrin Hygiene Private Limited, Skyline Holdings Pvt Ltd and 1 more | Director | 02 Aug 1997 | 29 Years 3 Months | Current |
Peer comparison
Tulips Medicaments Pvt Ltd is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| B.A.B. Agencies Private Limited | ₹1.28 Lakh (FY 2023) | 6.0% | Kolkata, West Bengal, India | |||
| Medivalue Healthcare Private Limited | ₹1.27 Lakh (FY 2024) | 15.0% | Lucknow, Uttar Pradesh, India | |||
| Octonova Healthcare Private Limited | ₹1.23 Lakh (FY 2024) | 9.0% | Delhi, India | |||
| Confervo Formulations Private Limited | ₹1.21 Lakh (FY 2021) | -91.0% | Chennai, Tamil Nadu, India | |||
| Salvavidas Industries Private Limited | ₹1.21 Lakh (FY 2025) | Surat, Gujarat, India | ||||
| Tulips Medicaments Pvt Ltdthis company | ₹1.2 Lakh (FY 2025) | -₹39,038 | -32.5% | Mumbai, Maharashtra, India | ||
| Novello Medica Private Limited | ₹1.2 Lakh (FY 2025) | Dehradun, Uttarakhand, India | ||||
| Rouland Oxides Private Limited | ₹1.2 Lakh (FY 2024) | Telangana, India | ||||
| Sward Formulations Private Limited | ₹1.19 Lakh (FY 2024) | Navi Mumbai, Maharashtra, India | ||||
| Zyden Gentec Limited | ₹1.18 Lakh (FY 2020) | -99.0% | Kota, Rajasthan, India | |||
| Medhexia Pharmaceuticals Private Limited | ₹1.17 Lakh (FY 2021) | 2.0% | Gurgaon, Haryana, India |
To see the full peer comparison of Tulips Medicaments Pvt Ltd, buy the company report.
Auditor
Tulips Medicaments Pvt Ltd is audited by BHAVIN SHAH ASSOCIATES for the financial year 2021.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| BHAVIN SHAH ASSOCIATES | FY 2021 | 115668W |
Shareholding
The shareholding of Tulips Medicaments Pvt Ltd is on record for 3 financial years, the latest being FY 2021, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Tulips Medicaments Pvt Ltd, buy the company report.
Legal cases
No court or tribunal cases involving Tulips Medicaments Pvt Ltd are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Tulips Medicaments Pvt Ltd; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Tulips Medicaments Pvt Ltd; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Tulips Medicaments Pvt Ltd has 4 board changes on record since 1997: 3 appointments and 1 cessation. The latest: Jignesh Mahendra Lakdawala ceased to be Director on 18 Jan 2011.
Frequently asked questions
Tulips Medicaments is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 18 February 1983 (43+ years old) and is registered under CIN U24239MH1983PTC029343.
Tulips Medicaments has 3 current directors:
- Krinita Karan Motwani - Director
- Pallavi Kirtikumar Lakdawala - Director
- Kirtikumar Manilal Lakdawala - Director
The latest financial statements of Tulips Medicaments on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Tulips Medicaments is U24239MH1983PTC029343. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Tulips Medicaments was incorporated on 18 February 1983, making it 43+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Tulips Medicaments by revenue are B.A.B. Agencies Private Limited, Medivalue Healthcare Private Limited, Octonova Healthcare Private Limited, Confervo Formulations Private Limited, Salvavidas Industries Private Limited and 5 more, all in the Pharma industry (Formulations).
Jignesh Mahendra Lakdawala ceased to be Director on 18 Jan 2011. Krinita Karan Motwani was appointed as Director on 27 Mar 2010. Pallavi Kirtikumar Lakdawala was appointed as Director on 27 Mar 2010. Tulips Medicaments has 4 board changes on record in total.
The registered office of Tulips Medicaments is at 774 Lakdi Bunderdarukhana Reay Road, Mumbai, Maharashtra, India – 400010.
Tulips Medicaments operates in the pharma industry, in the drug formulation and development segment.
The compliance status of Tulips Medicaments is compliant as of 12 July 2026. The company is actively filing with the Registrar of Companies.
Tulips Medicaments can be reached at its registered office: 774 Lakdi Bunderdarukhana Reay Road, Mumbai, Maharashtra, India – 400010.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
